Xencor Highlights CD28 Bispecific Antibody Platform at AACR

Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today presented new preclinical data... | April 17, 2023

Related Keywords

United States , Orlando , Florida , American , Xencor Xmab , John Desjarlais , American Association For Cancer Research , Nasdaq , Xencor Inc , American Association , Cancer Research , Annual Meeting , Xencor , Nc Stock Exchange , News , Information , Press Release , Iopharmaceutical , Company , Developing , Engineered , Antibodies , End , Ytokines , Or , The , Treatment , F , Dancer , Autoimmune , Oday , Resented , Few , Reclinical Xncr Us98401f1057 ,